Research Hub

Recovery & Tissue Repair Peptides

Recovery peptides are a category of compounds studied for their potential to accelerate healing of tendons, ligaments, muscle, and other connective tissues. The most well-known — BPC-157 and TB-500 (thymosin beta-4) — have generated significant interest in sports medicine and recovery research.

However, the evidence base for most recovery peptides is substantially weaker than for approved medications. Much of the research consists of animal studies and in vitro experiments, with limited human clinical trial data. Peptide Compass rates these compounds transparently to distinguish proven treatments from experimental ones.

Educational Content Only

This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.

How Recovery Peptides Are Thought to Work

BPC-157 (Body Protection Compound) is a synthetic peptide derived from human gastric juice that has shown angiogenic (blood vessel-forming) and tissue-protective effects in animal models. It may promote healing through upregulation of growth factors and modulation of the inflammatory response.

TB-500 is a synthetic version of thymosin beta-4, a protein involved in cell migration and wound healing. In animal studies, it has shown potential to promote tissue repair and reduce inflammation. Growth hormone secretagogues (GHS) like ipamorelin and CJC-1295 stimulate growth hormone release, which may support recovery indirectly.

Evidence Quality: What the Research Shows

The critical distinction for recovery peptides is that most lack human clinical trial data. BPC-157 has been studied extensively in animals — showing promise in tendon, muscle, and ligament healing models — but no large-scale human trials have been published. TB-500 similarly lacks robust human evidence.

This is why Peptide Compass rates these compounds as "Early Research" or "Investigational" rather than "Strong Evidence." The gap between animal studies and human outcomes is significant — many compounds that show promise in animals fail to replicate results in humans.

•BPC-157: Extensive animal data, minimal human trials. Not FDA-approved for any condition.
•TB-500 / Thymosin Beta-4: Animal wound-healing data, limited human studies. Not FDA-approved.
•Growth Hormone Secretagogues (ipamorelin, CJC-1295): Some human pharmacokinetic data, but not approved for recovery use.
•Growth Hormone (somatropin): FDA-approved for specific growth disorders, but not approved for athletic recovery enhancement.

Safety & Regulatory Status

None of the commonly discussed recovery peptides (BPC-157, TB-500) are FDA-approved for human use. They are classified as "research chemicals" and are not legal for use as dietary supplements or medications. Products sold online may be contaminated, mislabeled, or dosed inaccurately.

Growth hormone and growth hormone secretagogues carry additional risks including insulin resistance, joint pain, fluid retention, and potential effects on glucose metabolism. Use of growth hormone for athletic enhancement is prohibited by WADA and most sports organizations.

Anyone considering recovery peptides should consult a licensed healthcare provider. Legitimate medical treatment for sports injuries involves evidence-based approaches including physical therapy, proper rehabilitation protocols, and FDA-approved medications where appropriate.

Researched Compounds (9)

LL-37: A Multifaceted Host Defense Peptide

Peptide

Emerging Evidence

LL-37 is a human cathelicidin peptide that plays a crucial role in innate immunity by transporting cGAMP to activate STING signaling, enhancing antiviral immunity, and exhibiting antimicrobial activity. It is influenced by vitamin D and can also induce cytotoxic effects in certain cell types.

Ipamorelin

Peptide

Emerging Evidence

Ipamorelin is a growth hormone secretagogue peptide that stimulates the pituitary gland to release more of your own growth hormone. It's considered one of the milder GH-releasing peptides with fewer side effects than alternatives.

GHRP-6

Peptide

Emerging Evidence

GHRP-6 (Growth Hormone Releasing Hexapeptide) is a synthetic peptide that stimulates the release of growth hormone from the pituitary gland. Originally studied as a diagnostic tool for pituitary function, recent research has explored its potential in regenerative medicine, specifically for tissue repair, protection of renal cells, and muscle preservation through metabolic regulation.

GHRP-6 (Growth Hormone Releasing Peptide-6)

Peptide

Emerging Evidence

GHRP-6 is a synthetic peptide that stimulates the secretion of growth hormone. It has shown potential in diagnosing growth hormone deficiency, enhancing autophagy, providing cardioprotective effects, and promoting recovery from metabolic injuries.

CJC-1295

Peptide

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release more growth hormone. Popular in biohacker and athletic communities for recovery, muscle gain, and anti-aging effects.

TB-500

Peptide

A synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in wound healing, tissue repair, and inflammation reduction. Widely used in athletic recovery circles.

BPC-157

Peptide

BPC-157 is a synthetic peptide derived from a protein found in stomach acid. It's popular in biohacking communities for its purported healing and recovery benefits, but human clinical trial data remains very limited despite extensive animal research.

GHRP-6 (Growth Hormone Releasing Peptide-6)

Peptide

Emerging Evidence

GHRP-6 is a synthetic growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland. It has been studied for its potential use in treating growth hormone deficiency, cardiotoxicity, and muscle recovery.

MK-677 (Ibutamoren) Profile

Peptide

Emerging Evidence

MK-677 is an orally active growth hormone secretagogue known to improve nitrogen balance and promote growth hormone release. It has been associated with changes in body composition and some adverse effects, including potential hepatotoxicity.

Frequently Asked Questions

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any medical condition. While it has shown promising results in animal studies for tendon, ligament, and muscle healing, no large-scale human clinical trials have been completed. It is classified as a research chemical, not a medication or supplement.

What is the difference between BPC-157 and TB-500?

BPC-157 is a peptide derived from gastric juice with tissue-protective and angiogenic properties. TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell migration and wound healing. Both are studied for tissue repair, but neither has robust human clinical trial data. Some researchers study them in combination, though this is entirely experimental.

Do recovery peptides actually work for sports injuries?

There is insufficient human clinical evidence to determine whether recovery peptides like BPC-157 or TB-500 are effective for sports injuries. Animal studies are promising, but animal results frequently fail to translate to humans. Evidence-based recovery approaches include physical therapy, progressive loading protocols, adequate nutrition, sleep optimization, and FDA-approved treatments where medically indicated.

Are growth hormone secretagogues safe for recovery?

Growth hormone secretagogues (such as ipamorelin, CJC-1295, and similar compounds) are not FDA-approved for athletic recovery. They carry risks including insulin resistance, joint pain, fluid retention, and potential effects on glucose metabolism. Growth hormone itself is a prescription medication approved for specific medical conditions, not for performance enhancement. Use of these compounds for athletic purposes is prohibited by WADA.

Compare Compounds

Side-by-side analysis

Guided Pathways

Step-by-step research roadmap

Ask AI

AI research assistant

Peptide Compass provides educational content only and does not offer medical advice. All compound profiles are sourced from PubMed-indexed research. See our Editorial Policy and Medical Disclaimer.